A Phase 1 interventional study of Simvastatin and Placebo in Hypercholesterolemia, Dyslipidemia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-10-08.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing simvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. Simvastatin · Hypercholesterolemia.
Among the 50 studies testing simvastatin in Hypercholesterolemia, this one is the 38th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2009, is one of 2 in phase 1, and was the 38th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 50 studies testing simvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 30 Years to 70 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 240 across the 49 interventional studies. Of the 47 that completed or were terminated, 22 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
29 studies in Hypercholesterolemia by Merck & Co., Inc: 1 open now, 3 under way, 3 of them phase 3. Of 26 finished, 16 (62%) have results posted.
Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 25th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2009, is one of 6 in phase 1, and was the 12th registered.
Merck & Co., Inc’s Hypercholesterolemia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing simvastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 29 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to provide human lipidomics standards with simvastatin treatment that were to be used for comparison with similar preclinical studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Simvastatin 40 mg tablets once daily for 2 weeks followed by placebo for 2 weeks
Drug: Simvastatin · Drug: Placebo
Placebo for 2 weeks followed by simvastatin 40 mg once daily for 2 weeks
Drug: Simvastatin · Drug: Placebo
40 mg once daily for 2 weeks
Also known as: Zocor
Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
Arachidonic Acid Level After 2 Weeks of Treatment
Arachidonic acid level (20:4n6) in the cholesterol ester lipid class. The mean reported was an adjusted mean, which was obtained from running a 2-period crossover model that had fixed treatment and period terms and a random participant term.
Time frame: 2 weeks
Fasting Blood Lipidomic Levels After 2 Weeks of Treatment
Change in fasting blood cholesterol ester, lysophosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, and triacylglycerol levels compared to placebo. The mean reported was an adjusted mean.
Time frame: 2 weeks
Serum Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) Level
Two days of standardized, pre-packaged meals were provided prior to the 10-hour fast required before blood collection. To assess how consumption of a meal would affect levels of plasma PCSK9, following each of the fasting blood draws, participants were asked to consume a high fat meal (heavy whipping cream + vanilla ice cream in a 1:4 ratio \[dose = 162 g/m\^2\]) within 20 minutes. For the duration of the test, participants were to remain seated or recumbent until blood samples were drawn 4 h after meal completion. The mean reported was an adjusted mean (defined in first outcome measure).
Time frame: 2 weeks
Blood Linoleic Acid Levels
Change in blood linoleic acid levels for Cholesterol Ester compared to placebo.
Time frame: 2 weeks
Change in Fasting Delta 5 Desaturase Enzyme Activity Compared to Placebo
Change in fasting delta 5 desaturase enzyme activity compared to placebo. Delta 5 desaturase enzyme activity is defined as the ratios of C20:4n-6 to C20:3n-6 and C20:5n-3 to C20:4n-3.
Time frame: 2 weeks
| Milestone | Simvastatin 40 mg, Then Placebo | Placebo First, Then Simvastatin 40 mg |
|---|---|---|
| Started | 16 | 15 |
| Completed | 15 | 14 |
| Not completed | 1 | 1 |
| Withdrew: Administrative (scheduling conflict) | 1 | 1 |
| Milestone | Simvastatin 40 mg, Then Placebo | Placebo First, Then Simvastatin 40 mg |
|---|---|---|
| Started | 15 | 14 |
| Completed | 15 | 14 |
| Not completed | 0 | 0 |
Arachidonic acid level (20:4n6) in the cholesterol ester lipid class. The mean reported was an adjusted mean, which was obtained from running a 2-period crossover model that had fixed treatment and period terms and a random participant term.
| nmol | Simvastatin 40 mg | Placebo |
|---|---|---|
| Arachidonic Acid Level After 2 Weeks of Treatment | 259.1 ± 89.1 | 269.6 ± 85.2 |
Change in fasting blood cholesterol ester, lysophosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, and triacylglycerol levels compared to placebo. The mean reported was an adjusted mean.
| nmol | Simvastatin 40 mg | Placebo |
|---|---|---|
| Cholesterol ester lipid 16:00 | 288.9 ± 102.1 | 345.1 ± 87.3 |
| Cholesterol ester lipid 18:3n3 | 10.0 ± 4.8 | 14.4 ± 6.7 |
| Cholesterol ester lipid 20:3n6 | 20.9 ± 10.5 | 23.5 ± 10.2 |
| Cholesterol ester lipid 20:3n9 | 1.3 ± 1.1 | 1.2 ± 0.9 |
| Cholesterol ester lipid 22:5n6 | 1.0 ± 0.8 | 1.1 ± 0.4 |
| Cholesterol ester lipid 22:6n3 | 12.7 ± 5.1 | 14.8 ± 6.8 |
| Lysophosphatidyl-choline lipid 20:4n6 | 11.1 ± 3.8 | 10.3 ± 2.7 |
| Phosphatidyl-choline lipid 18:2n6 | 684.8 ± 224.9 | 824.9 ± 196.2 |
| Phosphatidyl-choline lipid 20:3n6 | 117.4 ± 54.3 | 127.1 ± 58.8 |
| Phosphatidyl-choline lipid 20:4n6 | 458.0 ± 138.4 | 443.2 ± 98.1 |
| Phosphatidyl-choline lipid 22:5n3 | 30.3 ± 10.2 | 34.3 ± 12.8 |
| Phosphatidyl-choline lipid 22:5n6 | 11.4 ± 6.4 | 12.1 ± 4.1 |
| Phosphatidyl-ethanolamine lipid 18:2n6 | 21.8 ± 9.3 | 32.1 ± 15.5 |
| Triacylglycerol 16:00 | 788.3 ± 431.6 | 1005.1 ± 662.2 |
| Triacylglycerol 20:3n9 | 4.5 ± 5.5 | 4.9 ± 2.8 |
Two days of standardized, pre-packaged meals were provided prior to the 10-hour fast required before blood collection. To assess how consumption of a meal would affect levels of plasma PCSK9, following each of the fasting blood draws, participants were asked to consume a high fat meal (heavy whipping cream + vanilla ice cream in a 1:4 ratio \[dose = 162 g/m\^2\]) within 20 minutes. For the duration of the test, participants were to remain seated or recumbent until blood samples were drawn 4 h after meal completion. The mean reported was an adjusted mean (defined in first outcome measure).
| nmol | Simvastatin 40 mg | Placebo |
|---|---|---|
| Fed | 6.06 ± 2.34 | 4.69 ± 1.66 |
| Fasted | 6.47 ± 2.11 | 5.51 ± 1.91 |
Change in blood linoleic acid levels for Cholesterol Ester compared to placebo.
| nmol | Simvastatin 40 mg | Placebo |
|---|---|---|
| Blood Linoleic Acid Levels | 1184.7 ± 393.4 | 1504.7 ± 327.8 |
Change in fasting delta 5 desaturase enzyme activity compared to placebo. Delta 5 desaturase enzyme activity is defined as the ratios of C20:4n-6 to C20:3n-6 and C20:5n-3 to C20:4n-3.
| ratio | Simvastatin 40 mg | Placebo |
|---|---|---|
| Cholesterol ester c20:4n6 / c20:3n6 | 12.2234 ± 3.413 | 11.5662 ± 3.684 |
| Cholesterol Ester c20:5n3/c20:4n3 | 17.9161 ± 7.738 | 16.3024 ± 9.465 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Simvastatin | — | 0/30 (0%) | 1/30 (3.3%) |
| Placebo | — | 0/30 (0%) | 2/30 (6.7%) |
| Event | Simvastatin | Placebo |
|---|---|---|
| Tension headacheNervous system disorders | 1/30 | 1/30 |
| DiarrhoeaGastrointestinal disorders | 0/30 | 1/30 |
| Age, Categorical(Participants) | All Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 31 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 0 |
| Male | 31 |
No study locations are listed for this record.
The record gives a start of Jul 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simvastatin